Glofitamab, Polatuzumab Vedotin and Zanubrutinib in First-line Elderly DLBCL
Status:
NOT_YET_RECRUITING
Trial end date:
2026-07-31
Target enrollment:
Participant gender:
Summary
This study aims to assess the efficacy and safety of the chemotherapy-light combination of glofitamab, polatuzumab vedotin and zanubrutinib (GPZ) in elderly patients with previously untreated diffuse large B-cell lymphoma.